Home Nav
Nextech Invest Logo


Nextech Invest's three globally active oncology funds use a unique combination of tailored investment strategy and pre-clinical and clinical cancer science expertise to tackle the challenges of investing equity in oncology

This de-risking strategy is executed by an investment team with pharmaceutical industry experience working closely with a dedicated scientific board of oncology experts.

By financing a pivotal process of cancer drug development, Nextech Invest thus increases the chance that novel, effective, vital drugs will reach the market, while at the same time offering attractive returns to investors.

Nextech III Oncology LPCI, Nextech Invest's second oncology-focused fund, commenced operations in April 2010. This Swiss limited partnership is fully regulated and operates under the supervision of the Swiss Financial Market Supervisory Authority FINMA.

Nextech IV Oncology, Nextech Invest’s third oncology fund, started operations in September 2014. The Partnership is regulated under the laws of the Grand Duchy of Luxembourg and is being supervised by the Luxembourg Supervisory Authority for the Financial Sector, the Commission de Surveillance du Secteur Financier (CSSF)

For inquiries please contact Alfred Scheidegger.

Log in
Important Legal Notice Nextech III Oncology Kommanditgesellschaft für kollektive Kapitalanlagen (the "LPCI") was authorised as a "limited partnership for collective investments" ("Kommanditgesellschaft für kollektive Kapitalanlagen") pursuant to Art. 13 of the Collective Investment Schemes Act ("CISA") and the limited partnership agreement was approved pursuant to Art. 15 CISA by decision of the Swiss Financial Market Supervisory Authority FINMA dated 31 March 2010.  Subscription for limited partnership interests in the LPCI is limited to "Qualified Investors" as defined in Art. 10 (3) and (4) CISA and Art. 6 of the implementing ordinance to the CISA and is further subject to the terms and conditions set out in the limited partnership agreement.

Nextech IV Oncology was established as SICAV-SIF under the laws and regulations of the Grand Duchy of Luxembourg and is compliant with Swiss law for distribution to qualified investors in Switzerland. The Swiss representative is Carnegie Fund Services S.A., 11, rue du Général-Dufour, 1204 Geneva. The Swiss paying agent is Banque Cantonale de Genève, 17, quai de l'Ile, 1204 Geneva. Investors in Switzerland can obtain the documents of the partnership, such as the issuing document, the LPA, the unaudited quarterly investor reports, and further information free of charge from the Swiss representative.
  • 20.04.2017

    Jounce Therapeutics initiates Phase 2 portion of ICONIC...

  • 19.04.2017

    Kura Oncology granted U.S. patent for clinical-stage...

  • 10.04.2017

    Tracon awarded 'Most Innovative Trial Design' for Phase...

Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close